Myeloma Questions and Controversies: New Developments in 2011 That Impact Diagnosis, Prognosis, and Treatment
This program is sponsored by Annenberg Center for Health Sciences and supported by International Myeloma Foundation (IMF).
| Location: |
San Diego Marriott Marquis & Marina, Marriott Hall |
| Speakers: |
Brian G.M. Durie, MD, Aptium Oncology, Inc., Los Angeles, CA
Philipe Moreau, MD, University Hospital Hôtel-Dieu, Nantes, France
Robert Z. Orlowski, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX
Antonio Palumbo, MD, University of Torino, Azienda Ospedaliero-Universitaria San Giovanni Battista, Torino, Italy
S. Vincent Rajkumar, MD, Mayo Clinic, Rochester, MN
Jesús F. San-Miguel, MD, PhD, University of Salamanca, Salamanca, Spain
|
This interactive, evidence-based symposium is designed to improve clinicians’ knowledge and competence in the latest developments, controversies, and novel approaches for diagnosing, treating, and determining prognosis for both newly diagnosed and relapsed/refractory multiple myeloma (MM). The agenda will cover the key areas in which clinical management of MM is undergoing the most change, including emerging approaches to smoldering myeloma, testing for diagnosis and prognosis, the evolving role of transplantation, maintenance or ongoing active treatment, and the development of new agents/regimens and their practical application in the clinical setting.
Contact: Eleanor Gallelli, International Myeloma Foundation/Clinical Care Options
Phone: 703-674-3524
E-mail: egallelli@clinicalcareoptions.com
back to top
International Hematologic Oncology Tumor Board: Practical Perspectives on Current Challenging Cases of Multiple Myeloma (Part Two of a Two-Part Series)
This program is sponsored by Research to Practice and supported by Mundipharma International Limited, Cephalon, Inc., Millennium: The Takeda Oncology Company, Celgene Corporation, and Genentech BioOncology/Biogen Idec.
| Location: |
Manchester Grand Hyatt San Diego, Douglas Pavilion |
| Speakers: |
Michele Cavo, MD, Bologna University School of Medicine, Bologna, Italy
Morie A. Gertz, MD, Mayo Clinic, Rochester, MN
Carol Ann Huff, MD, The Johns Hopkins University, Baltimore, MD
Nikhil C. Munshi, MD, Dana-Farber Cancer Institute, Boston, MA
David S. Siegel, MD, PhD, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
Pieter Sonneveld, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands
|
Research to Practice has devised a unique case-based symposia series that will explore the nuances of therapeutic decision making and address the current clinical ambiguities and multidisciplinary challenges faced by oncologists and hematologists around the globe routinely caring for patients with non-Hodgkin lymphoma (Part One) and multiple myeloma (Part Two).
Contact: Sylvia Eriksen, Research to Practice
Phone: 305-400-7345
E-mail:seriksen@researchtopractice.com
back to top
Oral Anticoagulant Therapy in Thromboembolic Disease: The Key Questions
This program is sponsored by University of Cincinnati Office of Continuing Medical Education and supported by Ortho-McNeil Janssen Scientific Affairs, LLC.
| Location: |
Manchester Grand Hyatt San Diego, Manchester Ballroom |
| Speakers: |
Kenneth A. Bauer, MD, Harvard Medical School, Boston, MA
Alex C. Spyropoulos, MD, Hamilton Hospital, Hamilton, Ontario
Jessica L. Mega, MD, Harvard Medical School, Boston, MA
Alexander G. G. Turpie, MD, McMaster University, Hamilton, Ontario, Canada
Jeffrey I. Weitz, MD, McMaster University, Hamilton, Ontario, Canada
|
This symposium will explore the role of novel oral anticoagulants across the spectrum of venous and arterial thromboembolic disease by posing – and, with reference to available data, addressing – a series of key questions of particular clinical and temporal relevance given the successful development (and, to differing extents, commercialization) of agents such as dabigatran, apixaban, and rivaroxaban.
Contact: Carol Ann Goode, The Exeter Group
Phone: 212-644-1017
E-mail:carol.goode@exeter-group.com
back to top
